Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized high-dose rifampicin safety trial in pulmonary tuberculosis
NL-OMON53704Phase 3Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rifampicin in pulmonary tuberculosis (TB) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Incidence of hepatotoxicity. Started Jan 2024; status: recruiting.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON53704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53704.